Xoma seeks $50M at threshold of pivotal gevokizumab readouts
Awaiting multiple gevokizumab (XOMA 052) data readouts in 2014, including the first Phase III data by midyear, on Friday Xoma Corp. priced a public offering of 9.5 million shares of common stock at $5.25 apiece, seeking to raise $50 million. The Berkeley, Calif.-based company granted underwriters a 30-day option to purchase up to an additional 1.4 million shares, potentially increasing its haul by $7.5 million.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST